A patient testing with ForeseeHome

A study has found that the ForeseeHome device detects neovascular AMD in patients who still have good visual acuity, and with greater sensitivity than the Amsler grid. 

Evaluated by Dr Marcus Altman, Casey Eye Institute, Oregon Health and Science University, US, Notal Vision’s ForeseeHome Preferential Hyperacuity Perimeter is operated at home by the patient for three minutes per eye per day. When shown a line of dots for 160 milliseconds, the patient uses a mouse to point to where the dots are misaligned. The perception of misalignments elsewhere, said Dr Altman, suggest areas of choroidal neovascularisation (CNV). Device alerts flag nAMD deterioration and prompt clinic visits.  

Presenting his findings at ARVO 2021, Dr Altman said that 78% of incident neovascular AMD cases were detected using the system, with a 22% false negative rate over the five years of study. He noted that the Amsler grid is known for its low sensitivity and specificity, which are not ideal for detecting CNV.